nodes	percent_of_prediction	percent_of_DWPC	metapath
Fidaxomicin—ABCB1—lung cancer	0.394	1	CbGaD
Fidaxomicin—ABCB1—Topotecan—lung cancer	0.0632	0.136	CbGbCtD
Fidaxomicin—ABCB1—Gefitinib—lung cancer	0.0578	0.124	CbGbCtD
Fidaxomicin—ABCB1—Vinorelbine—lung cancer	0.0445	0.0957	CbGbCtD
Fidaxomicin—ABCB1—Crizotinib—lung cancer	0.0354	0.0762	CbGbCtD
Fidaxomicin—ABCB1—Gemcitabine—lung cancer	0.0346	0.0745	CbGbCtD
Fidaxomicin—ABCB1—Erlotinib—lung cancer	0.0342	0.0735	CbGbCtD
Fidaxomicin—ABCB1—Paclitaxel—lung cancer	0.0313	0.0673	CbGbCtD
Fidaxomicin—ABCB1—Irinotecan—lung cancer	0.0309	0.0664	CbGbCtD
Fidaxomicin—ABCB1—Vinblastine—lung cancer	0.0274	0.059	CbGbCtD
Fidaxomicin—ABCB1—Cisplatin—lung cancer	0.0252	0.0541	CbGbCtD
Fidaxomicin—ABCB1—Etoposide—lung cancer	0.0247	0.0532	CbGbCtD
Fidaxomicin—ABCB1—Docetaxel—lung cancer	0.0226	0.0486	CbGbCtD
Fidaxomicin—ABCB1—Doxorubicin—lung cancer	0.0169	0.0363	CbGbCtD
Fidaxomicin—ABCB1—Methotrexate—lung cancer	0.0163	0.0351	CbGbCtD
Fidaxomicin—Hypersensitivity—Teniposide—lung cancer	0.000395	0.00281	CcSEcCtD
Fidaxomicin—Gastrointestinal haemorrhage—Docetaxel—lung cancer	0.000394	0.0028	CcSEcCtD
Fidaxomicin—Nausea—Pemetrexed—lung cancer	0.000393	0.0028	CcSEcCtD
Fidaxomicin—Nausea—Gefitinib—lung cancer	0.00039	0.00278	CcSEcCtD
Fidaxomicin—Nervous system disorder—Topotecan—lung cancer	0.000389	0.00277	CcSEcCtD
Fidaxomicin—Skin disorder—Topotecan—lung cancer	0.000386	0.00274	CcSEcCtD
Fidaxomicin—Nervous system disorder—Erlotinib—lung cancer	0.000385	0.00274	CcSEcCtD
Fidaxomicin—Anaemia—Vinorelbine—lung cancer	0.000385	0.00274	CcSEcCtD
Fidaxomicin—Neutropenia—Etoposide—lung cancer	0.000383	0.00273	CcSEcCtD
Fidaxomicin—Skin disorder—Erlotinib—lung cancer	0.000381	0.00272	CcSEcCtD
Fidaxomicin—Angioedema—Vinorelbine—lung cancer	0.00038	0.00271	CcSEcCtD
Fidaxomicin—Pruritus—Teniposide—lung cancer	0.000379	0.0027	CcSEcCtD
Fidaxomicin—Hepatobiliary disease—Cisplatin—lung cancer	0.000377	0.00268	CcSEcCtD
Fidaxomicin—Neutropenia—Paclitaxel—lung cancer	0.000376	0.00267	CcSEcCtD
Fidaxomicin—Hyperglycaemia—Paclitaxel—lung cancer	0.000362	0.00258	CcSEcCtD
Fidaxomicin—Immune system disorder—Irinotecan—lung cancer	0.000356	0.00253	CcSEcCtD
Fidaxomicin—Decreased appetite—Vinblastine—lung cancer	0.000355	0.00253	CcSEcCtD
Fidaxomicin—Dyspnoea—Topotecan—lung cancer	0.000354	0.00252	CcSEcCtD
Fidaxomicin—Unspecified disorder of skin and subcutaneous tissue—Vinorelbine—lung cancer	0.000352	0.0025	CcSEcCtD
Fidaxomicin—Dyspnoea—Erlotinib—lung cancer	0.00035	0.00249	CcSEcCtD
Fidaxomicin—Constipation—Vinblastine—lung cancer	0.000349	0.00249	CcSEcCtD
Fidaxomicin—Dyspepsia—Topotecan—lung cancer	0.000349	0.00249	CcSEcCtD
Fidaxomicin—Alanine aminotransferase increased—Docetaxel—lung cancer	0.000347	0.00247	CcSEcCtD
Fidaxomicin—Immune system disorder—Gemcitabine—lung cancer	0.000347	0.00247	CcSEcCtD
Fidaxomicin—Dyspepsia—Erlotinib—lung cancer	0.000346	0.00246	CcSEcCtD
Fidaxomicin—Hepatobiliary disease—Etoposide—lung cancer	0.000345	0.00246	CcSEcCtD
Fidaxomicin—Decreased appetite—Topotecan—lung cancer	0.000345	0.00246	CcSEcCtD
Fidaxomicin—Gastrointestinal disorder—Topotecan—lung cancer	0.000343	0.00244	CcSEcCtD
Fidaxomicin—Decreased appetite—Erlotinib—lung cancer	0.000341	0.00243	CcSEcCtD
Fidaxomicin—Vomiting—Teniposide—lung cancer	0.00034	0.00242	CcSEcCtD
Fidaxomicin—Dysphagia—Docetaxel—lung cancer	0.00034	0.00242	CcSEcCtD
Fidaxomicin—Constipation—Topotecan—lung cancer	0.000339	0.00242	CcSEcCtD
Fidaxomicin—Gastrointestinal disorder—Erlotinib—lung cancer	0.000339	0.00241	CcSEcCtD
Fidaxomicin—Hepatobiliary disease—Paclitaxel—lung cancer	0.000339	0.00241	CcSEcCtD
Fidaxomicin—Flatulence—Irinotecan—lung cancer	0.000338	0.00241	CcSEcCtD
Fidaxomicin—Rash—Teniposide—lung cancer	0.000338	0.0024	CcSEcCtD
Fidaxomicin—Dermatitis—Teniposide—lung cancer	0.000337	0.0024	CcSEcCtD
Fidaxomicin—Constipation—Erlotinib—lung cancer	0.000336	0.00239	CcSEcCtD
Fidaxomicin—Headache—Teniposide—lung cancer	0.000335	0.00239	CcSEcCtD
Fidaxomicin—Gastrointestinal pain—Vinblastine—lung cancer	0.000334	0.00238	CcSEcCtD
Fidaxomicin—Nervous system disorder—Vinorelbine—lung cancer	0.000333	0.00237	CcSEcCtD
Fidaxomicin—Skin disorder—Vinorelbine—lung cancer	0.00033	0.00235	CcSEcCtD
Fidaxomicin—Gastrointestinal pain—Topotecan—lung cancer	0.000325	0.00231	CcSEcCtD
Fidaxomicin—Immune system disorder—Cisplatin—lung cancer	0.000323	0.0023	CcSEcCtD
Fidaxomicin—Abdominal pain—Vinblastine—lung cancer	0.000323	0.0023	CcSEcCtD
Fidaxomicin—Gastrointestinal pain—Erlotinib—lung cancer	0.000321	0.00229	CcSEcCtD
Fidaxomicin—Neutropenia—Docetaxel—lung cancer	0.000318	0.00227	CcSEcCtD
Fidaxomicin—Nausea—Teniposide—lung cancer	0.000318	0.00226	CcSEcCtD
Fidaxomicin—Anaemia—Irinotecan—lung cancer	0.000317	0.00226	CcSEcCtD
Fidaxomicin—Abdominal pain—Topotecan—lung cancer	0.000314	0.00223	CcSEcCtD
Fidaxomicin—Malnutrition—Cisplatin—lung cancer	0.000312	0.00222	CcSEcCtD
Fidaxomicin—Abdominal pain—Erlotinib—lung cancer	0.00031	0.00221	CcSEcCtD
Fidaxomicin—Anaemia—Gemcitabine—lung cancer	0.000309	0.0022	CcSEcCtD
Fidaxomicin—Flatulence—Cisplatin—lung cancer	0.000307	0.00219	CcSEcCtD
Fidaxomicin—Dyspnoea—Vinorelbine—lung cancer	0.000303	0.00215	CcSEcCtD
Fidaxomicin—Hypersensitivity—Vinblastine—lung cancer	0.000301	0.00214	CcSEcCtD
Fidaxomicin—Immune system disorder—Etoposide—lung cancer	0.000296	0.00211	CcSEcCtD
Fidaxomicin—Decreased appetite—Vinorelbine—lung cancer	0.000295	0.0021	CcSEcCtD
Fidaxomicin—Gastrointestinal disorder—Vinorelbine—lung cancer	0.000293	0.00209	CcSEcCtD
Fidaxomicin—Hypersensitivity—Topotecan—lung cancer	0.000292	0.00208	CcSEcCtD
Fidaxomicin—Constipation—Vinorelbine—lung cancer	0.00029	0.00207	CcSEcCtD
Fidaxomicin—Immune system disorder—Paclitaxel—lung cancer	0.00029	0.00207	CcSEcCtD
Fidaxomicin—Anaemia—Cisplatin—lung cancer	0.000288	0.00205	CcSEcCtD
Fidaxomicin—Hepatobiliary disease—Docetaxel—lung cancer	0.000287	0.00204	CcSEcCtD
Fidaxomicin—Unspecified disorder of skin and subcutaneous tissue—Gemcitabine—lung cancer	0.000283	0.00201	CcSEcCtD
Fidaxomicin—Pruritus—Topotecan—lung cancer	0.000281	0.002	CcSEcCtD
Fidaxomicin—Malnutrition—Paclitaxel—lung cancer	0.00028	0.00199	CcSEcCtD
Fidaxomicin—Dysgeusia—Etoposide—lung cancer	0.000279	0.00199	CcSEcCtD
Fidaxomicin—Pruritus—Erlotinib—lung cancer	0.000278	0.00198	CcSEcCtD
Fidaxomicin—Gastrointestinal pain—Vinorelbine—lung cancer	0.000278	0.00198	CcSEcCtD
Fidaxomicin—Flatulence—Paclitaxel—lung cancer	0.000276	0.00196	CcSEcCtD
Fidaxomicin—Nervous system disorder—Irinotecan—lung cancer	0.000275	0.00195	CcSEcCtD
Fidaxomicin—Dysgeusia—Paclitaxel—lung cancer	0.000274	0.00195	CcSEcCtD
Fidaxomicin—Dizziness—Vinblastine—lung cancer	0.00027	0.00192	CcSEcCtD
Fidaxomicin—Abdominal pain—Vinorelbine—lung cancer	0.000268	0.00191	CcSEcCtD
Fidaxomicin—Nervous system disorder—Gemcitabine—lung cancer	0.000267	0.0019	CcSEcCtD
Fidaxomicin—Skin disorder—Gemcitabine—lung cancer	0.000265	0.00189	CcSEcCtD
Fidaxomicin—Anaemia—Etoposide—lung cancer	0.000264	0.00188	CcSEcCtD
Fidaxomicin—Unspecified disorder of skin and subcutaneous tissue—Cisplatin—lung cancer	0.000263	0.00187	CcSEcCtD
Fidaxomicin—Dizziness—Topotecan—lung cancer	0.000262	0.00187	CcSEcCtD
Fidaxomicin—Vomiting—Vinblastine—lung cancer	0.00026	0.00185	CcSEcCtD
Fidaxomicin—Dizziness—Erlotinib—lung cancer	0.00026	0.00185	CcSEcCtD
Fidaxomicin—Anaemia—Paclitaxel—lung cancer	0.000259	0.00184	CcSEcCtD
Fidaxomicin—Headache—Vinblastine—lung cancer	0.000256	0.00182	CcSEcCtD
Fidaxomicin—Angioedema—Paclitaxel—lung cancer	0.000256	0.00182	CcSEcCtD
Fidaxomicin—Vomiting—Topotecan—lung cancer	0.000252	0.0018	CcSEcCtD
Fidaxomicin—Rash—Topotecan—lung cancer	0.00025	0.00178	CcSEcCtD
Fidaxomicin—Hypersensitivity—Vinorelbine—lung cancer	0.00025	0.00178	CcSEcCtD
Fidaxomicin—Dermatitis—Topotecan—lung cancer	0.00025	0.00178	CcSEcCtD
Fidaxomicin—Vomiting—Erlotinib—lung cancer	0.00025	0.00178	CcSEcCtD
Fidaxomicin—Dyspnoea—Irinotecan—lung cancer	0.00025	0.00178	CcSEcCtD
Fidaxomicin—Nervous system disorder—Cisplatin—lung cancer	0.000249	0.00177	CcSEcCtD
Fidaxomicin—Headache—Topotecan—lung cancer	0.000249	0.00177	CcSEcCtD
Fidaxomicin—Rash—Erlotinib—lung cancer	0.000248	0.00176	CcSEcCtD
Fidaxomicin—Dermatitis—Erlotinib—lung cancer	0.000247	0.00176	CcSEcCtD
Fidaxomicin—Skin disorder—Cisplatin—lung cancer	0.000247	0.00176	CcSEcCtD
Fidaxomicin—Dyspepsia—Irinotecan—lung cancer	0.000246	0.00175	CcSEcCtD
Fidaxomicin—Immune system disorder—Docetaxel—lung cancer	0.000246	0.00175	CcSEcCtD
Fidaxomicin—Headache—Erlotinib—lung cancer	0.000246	0.00175	CcSEcCtD
Fidaxomicin—Gastrointestinal haemorrhage—Doxorubicin—lung cancer	0.000246	0.00175	CcSEcCtD
Fidaxomicin—Decreased appetite—Irinotecan—lung cancer	0.000243	0.00173	CcSEcCtD
Fidaxomicin—Dyspnoea—Gemcitabine—lung cancer	0.000243	0.00173	CcSEcCtD
Fidaxomicin—Nausea—Vinblastine—lung cancer	0.000243	0.00173	CcSEcCtD
Fidaxomicin—Gastrointestinal disorder—Irinotecan—lung cancer	0.000242	0.00172	CcSEcCtD
Fidaxomicin—Unspecified disorder of skin and subcutaneous tissue—Etoposide—lung cancer	0.000241	0.00172	CcSEcCtD
Fidaxomicin—Pruritus—Vinorelbine—lung cancer	0.00024	0.00171	CcSEcCtD
Fidaxomicin—Constipation—Irinotecan—lung cancer	0.000239	0.0017	CcSEcCtD
Fidaxomicin—Malnutrition—Docetaxel—lung cancer	0.000237	0.00169	CcSEcCtD
Fidaxomicin—Decreased appetite—Gemcitabine—lung cancer	0.000237	0.00169	CcSEcCtD
Fidaxomicin—Unspecified disorder of skin and subcutaneous tissue—Paclitaxel—lung cancer	0.000237	0.00168	CcSEcCtD
Fidaxomicin—Nausea—Topotecan—lung cancer	0.000236	0.00168	CcSEcCtD
Fidaxomicin—Gastrointestinal disorder—Gemcitabine—lung cancer	0.000235	0.00168	CcSEcCtD
Fidaxomicin—Constipation—Gemcitabine—lung cancer	0.000233	0.00166	CcSEcCtD
Fidaxomicin—Nausea—Erlotinib—lung cancer	0.000233	0.00166	CcSEcCtD
Fidaxomicin—Dry mouth—Paclitaxel—lung cancer	0.000233	0.00166	CcSEcCtD
Fidaxomicin—Dysgeusia—Docetaxel—lung cancer	0.000232	0.00165	CcSEcCtD
Fidaxomicin—Neutropenia—Methotrexate—lung cancer	0.000229	0.00163	CcSEcCtD
Fidaxomicin—Gastrointestinal pain—Irinotecan—lung cancer	0.000229	0.00163	CcSEcCtD
Fidaxomicin—Dyspnoea—Cisplatin—lung cancer	0.000227	0.00161	CcSEcCtD
Fidaxomicin—Skin disorder—Etoposide—lung cancer	0.000226	0.00161	CcSEcCtD
Fidaxomicin—Dizziness—Vinorelbine—lung cancer	0.000225	0.0016	CcSEcCtD
Fidaxomicin—Nervous system disorder—Paclitaxel—lung cancer	0.000224	0.00159	CcSEcCtD
Fidaxomicin—Skin disorder—Paclitaxel—lung cancer	0.000222	0.00158	CcSEcCtD
Fidaxomicin—Abdominal pain—Irinotecan—lung cancer	0.000221	0.00158	CcSEcCtD
Fidaxomicin—Decreased appetite—Cisplatin—lung cancer	0.000221	0.00157	CcSEcCtD
Fidaxomicin—Gastrointestinal disorder—Cisplatin—lung cancer	0.000219	0.00156	CcSEcCtD
Fidaxomicin—Anaemia—Docetaxel—lung cancer	0.000219	0.00156	CcSEcCtD
Fidaxomicin—Alanine aminotransferase increased—Doxorubicin—lung cancer	0.000217	0.00154	CcSEcCtD
Fidaxomicin—Vomiting—Vinorelbine—lung cancer	0.000216	0.00154	CcSEcCtD
Fidaxomicin—Rash—Vinorelbine—lung cancer	0.000214	0.00152	CcSEcCtD
Fidaxomicin—Dermatitis—Vinorelbine—lung cancer	0.000214	0.00152	CcSEcCtD
Fidaxomicin—Abdominal distension—Doxorubicin—lung cancer	0.000214	0.00152	CcSEcCtD
Fidaxomicin—Headache—Vinorelbine—lung cancer	0.000213	0.00151	CcSEcCtD
Fidaxomicin—Dysphagia—Doxorubicin—lung cancer	0.000212	0.00151	CcSEcCtD
Fidaxomicin—Dyspnoea—Etoposide—lung cancer	0.000208	0.00148	CcSEcCtD
Fidaxomicin—Hepatobiliary disease—Methotrexate—lung cancer	0.000207	0.00147	CcSEcCtD
Fidaxomicin—Hypersensitivity—Irinotecan—lung cancer	0.000206	0.00147	CcSEcCtD
Fidaxomicin—Dyspnoea—Paclitaxel—lung cancer	0.000204	0.00145	CcSEcCtD
Fidaxomicin—Decreased appetite—Etoposide—lung cancer	0.000202	0.00144	CcSEcCtD
Fidaxomicin—Nausea—Vinorelbine—lung cancer	0.000202	0.00144	CcSEcCtD
Fidaxomicin—Gastrointestinal disorder—Etoposide—lung cancer	0.000201	0.00143	CcSEcCtD
Fidaxomicin—Dyspepsia—Paclitaxel—lung cancer	0.000201	0.00143	CcSEcCtD
Fidaxomicin—Unspecified disorder of skin and subcutaneous tissue—Docetaxel—lung cancer	0.000201	0.00143	CcSEcCtD
Fidaxomicin—Constipation—Etoposide—lung cancer	0.000199	0.00142	CcSEcCtD
Fidaxomicin—Neutropenia—Doxorubicin—lung cancer	0.000199	0.00141	CcSEcCtD
Fidaxomicin—Decreased appetite—Paclitaxel—lung cancer	0.000199	0.00141	CcSEcCtD
Fidaxomicin—Dry mouth—Docetaxel—lung cancer	0.000197	0.00141	CcSEcCtD
Fidaxomicin—Gastrointestinal disorder—Paclitaxel—lung cancer	0.000197	0.0014	CcSEcCtD
Fidaxomicin—Constipation—Paclitaxel—lung cancer	0.000195	0.00139	CcSEcCtD
Fidaxomicin—Pruritus—Gemcitabine—lung cancer	0.000193	0.00137	CcSEcCtD
Fidaxomicin—Hyperglycaemia—Doxorubicin—lung cancer	0.000192	0.00136	CcSEcCtD
Fidaxomicin—Gastrointestinal pain—Etoposide—lung cancer	0.00019	0.00136	CcSEcCtD
Fidaxomicin—Nervous system disorder—Docetaxel—lung cancer	0.00019	0.00135	CcSEcCtD
Fidaxomicin—Skin disorder—Docetaxel—lung cancer	0.000188	0.00134	CcSEcCtD
Fidaxomicin—Hypersensitivity—Cisplatin—lung cancer	0.000187	0.00133	CcSEcCtD
Fidaxomicin—Gastrointestinal pain—Paclitaxel—lung cancer	0.000187	0.00133	CcSEcCtD
Fidaxomicin—Dizziness—Irinotecan—lung cancer	0.000185	0.00132	CcSEcCtD
Fidaxomicin—Abdominal pain—Etoposide—lung cancer	0.000184	0.00131	CcSEcCtD
Fidaxomicin—Abdominal pain—Paclitaxel—lung cancer	0.000181	0.00129	CcSEcCtD
Fidaxomicin—Hepatobiliary disease—Doxorubicin—lung cancer	0.000179	0.00128	CcSEcCtD
Fidaxomicin—Vomiting—Irinotecan—lung cancer	0.000178	0.00127	CcSEcCtD
Fidaxomicin—Immune system disorder—Methotrexate—lung cancer	0.000177	0.00126	CcSEcCtD
Fidaxomicin—Rash—Irinotecan—lung cancer	0.000177	0.00126	CcSEcCtD
Fidaxomicin—Dermatitis—Irinotecan—lung cancer	0.000176	0.00126	CcSEcCtD
Fidaxomicin—Headache—Irinotecan—lung cancer	0.000175	0.00125	CcSEcCtD
Fidaxomicin—Vomiting—Gemcitabine—lung cancer	0.000173	0.00123	CcSEcCtD
Fidaxomicin—Dyspnoea—Docetaxel—lung cancer	0.000173	0.00123	CcSEcCtD
Fidaxomicin—Rash—Gemcitabine—lung cancer	0.000172	0.00122	CcSEcCtD
Fidaxomicin—Dermatitis—Gemcitabine—lung cancer	0.000172	0.00122	CcSEcCtD
Fidaxomicin—Hypersensitivity—Etoposide—lung cancer	0.000172	0.00122	CcSEcCtD
Fidaxomicin—Malnutrition—Methotrexate—lung cancer	0.000171	0.00122	CcSEcCtD
Fidaxomicin—Headache—Gemcitabine—lung cancer	0.000171	0.00122	CcSEcCtD
Fidaxomicin—Dyspepsia—Docetaxel—lung cancer	0.00017	0.00121	CcSEcCtD
Fidaxomicin—Decreased appetite—Docetaxel—lung cancer	0.000168	0.0012	CcSEcCtD
Fidaxomicin—Hypersensitivity—Paclitaxel—lung cancer	0.000168	0.0012	CcSEcCtD
Fidaxomicin—Dysgeusia—Methotrexate—lung cancer	0.000167	0.00119	CcSEcCtD
Fidaxomicin—Gastrointestinal disorder—Docetaxel—lung cancer	0.000167	0.00119	CcSEcCtD
Fidaxomicin—Nausea—Irinotecan—lung cancer	0.000166	0.00118	CcSEcCtD
Fidaxomicin—Constipation—Docetaxel—lung cancer	0.000166	0.00118	CcSEcCtD
Fidaxomicin—Pruritus—Etoposide—lung cancer	0.000165	0.00117	CcSEcCtD
Fidaxomicin—Nausea—Gemcitabine—lung cancer	0.000162	0.00115	CcSEcCtD
Fidaxomicin—Vomiting—Cisplatin—lung cancer	0.000162	0.00115	CcSEcCtD
Fidaxomicin—Pruritus—Paclitaxel—lung cancer	0.000162	0.00115	CcSEcCtD
Fidaxomicin—Rash—Cisplatin—lung cancer	0.00016	0.00114	CcSEcCtD
Fidaxomicin—Dermatitis—Cisplatin—lung cancer	0.00016	0.00114	CcSEcCtD
Fidaxomicin—Gastrointestinal pain—Docetaxel—lung cancer	0.000158	0.00113	CcSEcCtD
Fidaxomicin—Anaemia—Methotrexate—lung cancer	0.000158	0.00112	CcSEcCtD
Fidaxomicin—Dizziness—Etoposide—lung cancer	0.000154	0.0011	CcSEcCtD
Fidaxomicin—Immune system disorder—Doxorubicin—lung cancer	0.000154	0.00109	CcSEcCtD
Fidaxomicin—Abdominal pain—Docetaxel—lung cancer	0.000153	0.00109	CcSEcCtD
Fidaxomicin—Dizziness—Paclitaxel—lung cancer	0.000151	0.00107	CcSEcCtD
Fidaxomicin—Nausea—Cisplatin—lung cancer	0.000151	0.00107	CcSEcCtD
Fidaxomicin—Vomiting—Etoposide—lung cancer	0.000148	0.00105	CcSEcCtD
Fidaxomicin—Malnutrition—Doxorubicin—lung cancer	0.000148	0.00105	CcSEcCtD
Fidaxomicin—Rash—Etoposide—lung cancer	0.000147	0.00105	CcSEcCtD
Fidaxomicin—Dermatitis—Etoposide—lung cancer	0.000147	0.00104	CcSEcCtD
Fidaxomicin—Headache—Etoposide—lung cancer	0.000146	0.00104	CcSEcCtD
Fidaxomicin—Flatulence—Doxorubicin—lung cancer	0.000146	0.00104	CcSEcCtD
Fidaxomicin—Vomiting—Paclitaxel—lung cancer	0.000145	0.00103	CcSEcCtD
Fidaxomicin—Dysgeusia—Doxorubicin—lung cancer	0.000145	0.00103	CcSEcCtD
Fidaxomicin—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—lung cancer	0.000145	0.00103	CcSEcCtD
Fidaxomicin—Rash—Paclitaxel—lung cancer	0.000144	0.00102	CcSEcCtD
Fidaxomicin—Dermatitis—Paclitaxel—lung cancer	0.000144	0.00102	CcSEcCtD
Fidaxomicin—Headache—Paclitaxel—lung cancer	0.000143	0.00102	CcSEcCtD
Fidaxomicin—Hypersensitivity—Docetaxel—lung cancer	0.000143	0.00102	CcSEcCtD
Fidaxomicin—Nausea—Etoposide—lung cancer	0.000138	0.000985	CcSEcCtD
Fidaxomicin—Pruritus—Docetaxel—lung cancer	0.000137	0.000975	CcSEcCtD
Fidaxomicin—Nervous system disorder—Methotrexate—lung cancer	0.000137	0.000974	CcSEcCtD
Fidaxomicin—Anaemia—Doxorubicin—lung cancer	0.000137	0.000974	CcSEcCtD
Fidaxomicin—Nausea—Paclitaxel—lung cancer	0.000136	0.000966	CcSEcCtD
Fidaxomicin—Skin disorder—Methotrexate—lung cancer	0.000136	0.000965	CcSEcCtD
Fidaxomicin—Dizziness—Docetaxel—lung cancer	0.000128	0.000911	CcSEcCtD
Fidaxomicin—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—lung cancer	0.000125	0.000891	CcSEcCtD
Fidaxomicin—Dyspnoea—Methotrexate—lung cancer	0.000124	0.000885	CcSEcCtD
Fidaxomicin—Dry mouth—Doxorubicin—lung cancer	0.000123	0.000877	CcSEcCtD
Fidaxomicin—Vomiting—Docetaxel—lung cancer	0.000123	0.000876	CcSEcCtD
Fidaxomicin—Dyspepsia—Methotrexate—lung cancer	0.000123	0.000874	CcSEcCtD
Fidaxomicin—Rash—Docetaxel—lung cancer	0.000122	0.000869	CcSEcCtD
Fidaxomicin—Dermatitis—Docetaxel—lung cancer	0.000122	0.000868	CcSEcCtD
Fidaxomicin—Decreased appetite—Methotrexate—lung cancer	0.000121	0.000863	CcSEcCtD
Fidaxomicin—Headache—Docetaxel—lung cancer	0.000121	0.000863	CcSEcCtD
Fidaxomicin—Gastrointestinal disorder—Methotrexate—lung cancer	0.00012	0.000857	CcSEcCtD
Fidaxomicin—Nervous system disorder—Doxorubicin—lung cancer	0.000118	0.000843	CcSEcCtD
Fidaxomicin—Skin disorder—Doxorubicin—lung cancer	0.000117	0.000835	CcSEcCtD
Fidaxomicin—Nausea—Docetaxel—lung cancer	0.000115	0.000818	CcSEcCtD
Fidaxomicin—Gastrointestinal pain—Methotrexate—lung cancer	0.000114	0.000812	CcSEcCtD
Fidaxomicin—Abdominal pain—Methotrexate—lung cancer	0.00011	0.000785	CcSEcCtD
Fidaxomicin—Dyspnoea—Doxorubicin—lung cancer	0.000108	0.000767	CcSEcCtD
Fidaxomicin—Dyspepsia—Doxorubicin—lung cancer	0.000106	0.000757	CcSEcCtD
Fidaxomicin—Decreased appetite—Doxorubicin—lung cancer	0.000105	0.000748	CcSEcCtD
Fidaxomicin—Gastrointestinal disorder—Doxorubicin—lung cancer	0.000104	0.000742	CcSEcCtD
Fidaxomicin—Constipation—Doxorubicin—lung cancer	0.000103	0.000735	CcSEcCtD
Fidaxomicin—Hypersensitivity—Methotrexate—lung cancer	0.000103	0.000732	CcSEcCtD
Fidaxomicin—Gastrointestinal pain—Doxorubicin—lung cancer	9.88e-05	0.000703	CcSEcCtD
Fidaxomicin—Pruritus—Methotrexate—lung cancer	9.87e-05	0.000703	CcSEcCtD
Fidaxomicin—Abdominal pain—Doxorubicin—lung cancer	9.55e-05	0.00068	CcSEcCtD
Fidaxomicin—Dizziness—Methotrexate—lung cancer	9.23e-05	0.000657	CcSEcCtD
Fidaxomicin—Hypersensitivity—Doxorubicin—lung cancer	8.9e-05	0.000634	CcSEcCtD
Fidaxomicin—Vomiting—Methotrexate—lung cancer	8.87e-05	0.000631	CcSEcCtD
Fidaxomicin—Rash—Methotrexate—lung cancer	8.8e-05	0.000626	CcSEcCtD
Fidaxomicin—Dermatitis—Methotrexate—lung cancer	8.79e-05	0.000626	CcSEcCtD
Fidaxomicin—Headache—Methotrexate—lung cancer	8.74e-05	0.000622	CcSEcCtD
Fidaxomicin—Pruritus—Doxorubicin—lung cancer	8.55e-05	0.000608	CcSEcCtD
Fidaxomicin—Nausea—Methotrexate—lung cancer	8.29e-05	0.00059	CcSEcCtD
Fidaxomicin—Dizziness—Doxorubicin—lung cancer	7.99e-05	0.000569	CcSEcCtD
Fidaxomicin—Vomiting—Doxorubicin—lung cancer	7.68e-05	0.000547	CcSEcCtD
Fidaxomicin—Rash—Doxorubicin—lung cancer	7.62e-05	0.000542	CcSEcCtD
Fidaxomicin—Dermatitis—Doxorubicin—lung cancer	7.61e-05	0.000542	CcSEcCtD
Fidaxomicin—Headache—Doxorubicin—lung cancer	7.57e-05	0.000539	CcSEcCtD
Fidaxomicin—Nausea—Doxorubicin—lung cancer	7.18e-05	0.000511	CcSEcCtD
